1. Background {#s0005}
=============

Tobacco-related diseases such as cancers, heart disease, and lung diseases are the leading cause of death among individuals with mental illness ([@b0070], [@b0240]). In addition, individuals with mental illness face tobacco-related isolation, stigma, or financial hardships ([@b0260]). Tobacco use is also reported to increase the metabolism of some psychiatric medication ([@b0260]). While it is estimated that individuals with mental illness make up only 22% of the United States' population, estimates are that each year 200,000 of the 443,000 tobacco-related deaths are among individuals with mental illness ([@b0290], [@b0345]). Smoking cessation programs are however rare in inpatient psychiatry and substance use treatment facilities including in facilities where smoking is not allowed ([@b0250], [@b0255]). The objective of this review was a narrative overview or examination of evidence of smoking cessation interventions in psychiatric inpatient treatment facilities.

The historical culture of permitting smoking in psychiatry units has led to more than half of psychiatry facilities in the US permitting smoking in their units ([@b0255]). Individuals with mental illness are more likely to smoke compared to the general population and their smoking rates remain consistently high ([@b0215], [@b0320]). Up to 85% of individuals with mental illness are current cigarette smokers ([@b0160], [@b0190], [@b0205]), a rate that is 4 times higher than the general population ([@b0050], [@b0205]). Other studies reported that 60% of adolescents in inpatient psychiatric care were current smokers with 40% smoking at least a pack of cigarettes each day ([@b0245], [@b0265]). While there have been declining smoking trends in the general population, such has not been observed among people with psychiatric illness ([@b0075], [@b0320]). Some research has shown that when there is a failure to address tobacco dependence, majority of psychiatric patients who quit smoking as inpatients relapse following their hospital discharge, and unaddressed nicotine dependence compromises psychiatric care ([@b0250], [@b0260]). Given such high rates of smoking and the difficulty to quit, there is a need to understand how smoking cessation interventions work, and are implemented among this population of individuals with psychiatric illness in inpatient settings.

2. Smoking in inpatient psychiatry settings {#s0010}
===========================================

Smoking has been a widely accepted culture in psychiatry units including in some cases clinicians smoking with patients ([@b0045], [@b0080]). The Joint Commission which is the entity responsible for accreditation and certification of US healthcare Organizations' mandate in 1992 for hospitals to ban smoking in the United States was met with so much advocacy for patients' need and right to smoke ([@b0045]). Such advocacy and outcries later led the Joint Commission to exempt psychiatry units from the smoking ban ([@b0045], [@b0175], [@b0325]). In most cases, cigarette smoking has been used to reward patients for good behavior in these psychiatry units or as a privilege to reinforce patients' medication use compliance ([@b0230]). Clinicians who smoke with patients within psychiatric inpatient facilities reported that smoking together is a good way to build clinician and patient rapport ([@b0080], [@b0255]). In addition, tobacco use treatment is ignored or delayed by many clinicians who do not view the dependence as a disorder in the area of mental illness treatment ([@b0345]). Other reasons for delayed treatment include lack of education or knowledge of association between smoking and psychiatric disorders, and nicotine dependence medical-related complications ([@b0145], [@b0285]).

3. Methods {#s0015}
==========

This paper is a narrative overview of smoking cessation randomized control trial studies that started at least in psychiatry inpatient settings. We searched PubMed, PsychINFO, and CINAHL for articles of smoking cessation studies in inpatient psychiatry settings published between 1950 and December 2018. Search terms and phrases used included; smoking cessation in inpatient psychiatry, smoking cessation in inpatient mental health treatment facilities, smoking cessation and mental health, smoking cessation and substance use treatment, and tobacco treatment in inpatient psychiatry treatment facilities. The search terms also included smoking cessation clinical trials or randomized trials in inpatient psychiatry.

3.1. Inclusion and exclusion {#s0020}
----------------------------

The final journal articles included in this paper were those of randomized controlled trials that at least started in inpatient psychiatry settings and were published between 1950 and December 2018. Any studies that were not randomized controlled trials or did not start in inpatient settings were excluded. To avoid duplication, only one manuscript was reviewed from each randomized controlled study found during the searches. Studies of smoking cessation among outpatient settings were also excluded.

4. Results {#s0025}
==========

Following the exclusion and inclusion criteria, a total of eight (8) peer reviewed journal articles were reviewed and included in this paper. Of the 120 articles found, 112 were excluded, and all included were randomized controlled trials. One study was among adolescent psychiatric inpatient smokers ages 13--17, and 7 studies were among adult psychiatric inpatients with mean age 41 years. A summary of the included studies is shown in [Table 1](#t0005){ref-type="table"}. As indicated in the inclusion criteria, all the 8 studies included started at least when participants were in inpatient settings and lasted between 8 and 12 weeks. Treatment continued after discharge in some cases with follow up periods between 1 and 18 months. Of the controlled trials included in the review, 7 out of 8 used a combination of behavioral and pharmacological interventions, and one study had only pharmacological interventions. In 7 of the studies the pharmacological interventions were nicotine replacement therapies (NRT), and one study used varenicline as the pharmacological intervention. At baseline, participants smoked an average of 18.1 cigarettes per day, and up to 85% of individuals with psychiatric illness were current cigarette smokers. The exclusion criteria used by authors in the studies we reviewed were based on issues such as serious medical contraindications to NRT, or severe aggression during the hospital stay ([@b0295]). Additional exclusion criteria used by authors in the reviewed studies included participants being young than 18 years and not fluent in the English language ([@b0255]).Table 1Summary of smoking cessation clinical trial studies in inpatient psychiatry and substance use treatment facilities.Author (year published)Outcome MeasuresSettingPopulationMean AgeMean cigarettes per dayTreatment TypeFollow-up (months)Sample size[@b0215]1-Month prolonged abstinence\
7-day point prevalence abstinenceStarted in inpatient psychiatric facilities and continued post-dischargeInpatients at 4 psychiatric facilities in Australia38.7Usual care compared to brief MI plus 4-month pharmacological & psychosocial intervention post discharge4, 6--12754[@b0295]Number of 24 h quit attemptsStarted in Inpatient psychiatryAdult inpatients from seven from seven psychiatric units at 3 San Francisco Bay Area hospitals.3917Usual care compared to brief (3 months) treatment group, and extended (6 months) treatment group.\
Treatment groups received transtheoretical-model tailored computer intervention. NRT was given to participants18956[@b0305]Reduce smoking and improvement of cognitionA meaningful portion of the sample were inpatientsPatients with schizophrenia45.117.6Varenicline compared to placebo8-weeks treatment87[@b0135]7-day point prevalence abstinenceFrom three psychiatric units at San Francisco General Hospital. 10-week post hospital NRTAdult smokers uninsured, indigent, unhoused39.519NRT + Advice compared to Transtheoretical -- model tailored computer-assisted intervention100[@b0315]7-day point prevalence abstinenceInitiated in inpatient care and continued for 4-months post-dischargePatient smokers at an inpatient psychiatric facility in Australia37.623.0Usual Treatment compared to psychosocial and pharmacological (NRT) support205[@b0255]Verified 7-day point prevalence abstinenceInitiated in Inpatient Psychiatry and continued in outpatient treatment\
10-week post NRT?Patients in locked acute psychiatry unit at the Langley Porter Psychiatric Institute at the University of California19.0Usual care compared to (Motivational interviewing + NRT)18-months\
NRT was provided for 10 weeks224[@b0055]Smoking reduction, and 7-day point prevalence abstinenceInpatients with schizophrenia and schizoaffective disordersTwo public inpatient psychiatry facilities in Taiwan45.213.1High dose NRT (31.2 mg) compared to Low dose NRT (20.8 mg)8-weeks treatment184[@b0040]Point prevalence abstinence, quit attempts, change in smoking rate, and longest quit attemptPsychiatry inpatientAdolescents at a private university hospital in Providence Rhode Island13--17Motivational Interviewing (MI) versus brief advice (BA). MI was two 45 min sessions and BA was 5--10 min advice with quit information. NRT was provided at discharge1, 3, 6, 9, and 12191

5. Discussion {#s0030}
=============

5.1. Smoking cessation in psychiatric inpatient facilities {#s0035}
----------------------------------------------------------

The goal of this review was an examination of existing evidence of smoking cessation interventions in psychiatric inpatient treatment facilities. In this review we found that smokers with psychiatric illness in psychiatric treatment facilities rarely receive smoking cessation treatment and effective services are needed to assist them quit ([@b0210]). Hospitals offering inpatient services have been identified as opportunity settings to begin tobacco dependence treatment and as settings where smokers are motivated to quit or accept quitting messages ([@b0030], [@b0085]). However, few studies reported initiation of smoking cessation treatments while participants were inpatients in psychiatric facilities and continued treatment for at least 4--6 months post-psychiatric hospital discharge ([@b0135], [@b0215], [@b0255], [@b0315]). In some of these studies, psychiatric patient participants were recruited regardless of their intention to quit smoking ([@b0025], [@b0135]). The limited research regarding smoking cessation among people with mental illness shows this group is just as interested in quitting and in a few cases have quit attempt rates similar to smokers without mental illness ([@b0205], [@b0215], [@b0300]).

5.2. Tobacco use treatment {#s0040}
--------------------------

Like in the general population, smokers with psychiatric illness use both pharmacological and psychosocial strategies in their attempts to quit smoking ([@b0215], [@b0295], [@b0315]). Results from clinical trials have shown smoking quit rates of these strategies to be between 4% and 22% among people with psychiatric illness ([@b0020], [@b0025]). In patients with schizophrenia disorders for example, bupropion and varenicline have been found to be effective pharmacotherapies for smoking cessation ([@b0025], [@b0115], [@b0330], [@b0340]). Treatment modalities that use a combination of psychosocial and pharmacotherapies are effective in increasing abstinence rates. In outpatient settings for example, depressed smokers who received cognitive-behavioral and nicotine replacement therapies doubled cessation rates ([@b0135]). On the other hand, smokers with schizophrenia who were treated with a combination of buproprion and nicotine replacement therapy (NRT) had more abstinence rates compared to schizophrenia smokers treated only with NRT ([@b0110], [@b0135]).

5.3. Psychosocial or behavioral intervention {#s0045}
--------------------------------------------

Psychosocial or behavioral interventions included motivational interviewing (MI) and brief advice (BA). Brown et al. defined the motivational interviewing they used as two 45 min long counseling sessions and brief advice as 5--10 min brief advice on quitting smoking in combination with useful information on quiting ([@b0040]). This brief advice is what is at times referred to as usual care because study staff give advice to smokers to quit in addition to provided quit smoking pamphlets ([@b0135]). MI is generally defined as client centered techniques that increase motivation especially among patients or clients with substance use disorders and lack the motivation to change their behavior ([@b0040]). MI is said to target cognitive processes and help the client evaluate the perceived behavioral costs and benefits of changing behavior ([@b0015], [@b0040], [@b0335]) MI is reported to be effective in increasing the readiness of changing behavior ([@b0040], [@b0095]).

Smokers with substance use disorders (SUD) have lower motivation to quit, a predictor of low success for smoking cessation ([@b0120], [@b0195], [@b0270], [@b0280]). In this group of smokers therefore, treatment methods such as motivational interviewing (MI) or brief advice (BA) that are geared to increase motivation are very much needed ([@b0060], [@b0280]). In one study, researchers found that there was no significant differences between MI and BA for a 7-day abstinence from smoking for follow ups within 1, 3, 6, and 12 months periods ([@b0275]). These same researchers reported that while the difference between MI and BA is minimal, BA might be a better choice for alcoholics in SUD treatment because of its strong authoritative nature compared to MI's softer therapeutic and choice guided approach ([@b0065], [@b0220], [@b0275]). In smokers with SUD, contingent vouchers (cv) was found to significantly increase smoking abstinence only during the period that incentives were available, and such increase dropped soon following termination of the incentives ([@b0005], [@b0010], [@b0105], [@b0100], [@b0280]).

5.4. Pharmacological strategies {#s0050}
-------------------------------

Pharmacological interventions are divided into two categories, the nicotine replacement therapy (NRT), and the non-nicotine medications. There are 5 NRT products approved by the US Food and Drug Administration (FDA) and they include: nicotine patches, nicotine gum, nicotine nasal spray, nicotine lozenges, and nicotine vapor inhaler ([@b0155]). The FDA approved non-nicotine medicines are, bupropion, and varenicline ([@b0155]). In patients with schizophrenia, varenicline has been used and found to significantly decrease cotinine levels (p \< 0.01), and objective or subjective measures of smoking (p \< 0.01) in those patients who were smokers ([@b0305]). All NRT products and medicines can be obtained in different doses for example the NRT patch comes in 21, 14, and 7 mg ([@b0225]), and nicotine gum in 6, 4, and 2 mg ([@b0130]). While there was a dose effect of NRT patches among the general population of smokers, a higher dose of NRT (31.2 mg) did not produce significant differences compared to a lower dose (20.8 mg) among patients with schizophrenia or schizoaffective disorders ([@b0055], [@b0125]). As shown in the reviewed studies, some of the cessation strategies described in this paper and used in the general population are same as those in the psychiatric inpatient settings. The NRT dose effect example described here is however some of the evidence of a need for evidence-based interventions tailored to this population of psychiatric inpatients to help them quit smoking.

5.5. Gaps/challenges {#s0055}
--------------------

This population of psychiatric inpatients who smoke have some of the greatest disparities associated with cigarette smoking yet we found only eight randomized control trial studies. This calls for additional RCT research in this area. Clinical trial research of smoking cessation is rare among individuals with psychiatric illness, and even the limited research has been mainly among outpatients and left out inpatients ([@b0055]).

The limited research available shows that individuals with psychiatric illness experience the greatest exclusion in studies of smoking cessation ([@b0165], [@b0180]). A critical issue deserving additional research and likely to improve cessation treatment among this population is an investigation of the appropriate timing to begin cessation treatment following a patient's inpatient admission ([@b0090]). With the current trend of psychiatric hospitals going smoke free ([@b0170], [@b0310]), there is likely an increase of psychiatric inpatients experiencing nicotine withdrawal symptoms ([@b0310]). Some of the symptoms of nicotine withdrawal are severe and might include increased feelings of anger, anxiety, restlessness, depressed mood, sleep disturbances, increased appetite, difficulty concentrating and craving ([@b0150], [@b0310]). These symptoms generally occur in the first 24 h of nicotine deprivation and severe in the first week of abstinence ([@b0140], [@b0310]). There is need for an investigation of the effect of these symptoms in the general health of this population and their overall success in quitting smoking. Studies have indicated that the cessation treatments used among the mentally ill patients are the same as those among the general population yet individuals with mental illness are a unique population deserving of unique interventions ([@b0235]), or intensive treatment approaches ([@b0200]). In comparison other medically ill patients who achieve short-term abstinence while inpatients have increased success for quitting yet for those with behavioral or mental health diagnoses the cessation likelihood is low ([@b0035], [@b0185], [@b0350]).

6. Conclusion {#s0060}
=============

Smoking cessation in inpatient settings is rare or delayed for reasons such as lack of knowledge of associations between smoking and psychiatric disorders. Although retention in smoking cessation studies can be difficult, psychiatric inpatient smokers can be engaged in cessation studies. Quitting smoking is difficult for individuals with psychiatric illness but they are just as interested in quitting as the general population and in some cases show quit attempts like those of the general population. While there was a dose effect of NRT patches among the general population of smokers, higher dose of NRT did not produce significant differences compared to a lower NRT dose among patients with schizophrenia or schizoaffective disorders. Tailored interventions with consideration of psychiatric inpatient specific needs are needed and may be helpful for psychiatric patients to quit smoking.
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